Global Nanoemulsion Market: Snapshot
There are various ways in which established players are trying to increase their stronghold over the global market for Nanoemulsion. Expanding outreach in developing markets that offer enormous opportunities to grow is one of them. Besides, they also have a strong pipeline of nanoemulsion based vaccines against influenza, anthrax, chlamydia infection, several sexually transmitted infections, and respiratory diseases.
There are many factors currently boosting the global Nanoemulsion market. Some of them are the technological progress in the pharmaceutical and biotechnology industry, rising instances of chronic diseases, increasing awareness about their treatments, growing demand for more target specific drug delivery systems, and supportive policies of governments. New product launches is also proving to be immensely beneficial for the market.
The other factors responsible for the growth in the market include higher allocations for healthcare infrastructure, rising economic stability, and increasing participation of major market players in in developing economies such as Latin America and the Middle East and Africa.
On account of the aforementioned growth drivers, a report by Transparency Market Research projects the global Nanoemulsion market to rise at a healthy 9.2% CAGR from 2017 and 2025 to become worth US$14.91 bn by 2025 from US$6.78 bn in 2016.
Immunosuppressant See Maximum Uptake
The global market for Nanoemulsion can be segmented based on different parameters. Depending upon the type of drugs, for example, it can be segmented into steroids, anesthetics, NSAIDs, antiretroviral, antimicrobials, vasodilators, immunosuppressant, etc. Of them, the segment of NSAIDs is slated to outpace all others vis-à-vis growth rate by registering a CAGR of 10.1% from 2017 to 2025. This is because of the rising use Nanoemulsion formulation in topical and other drug administration routes for more effective drug delivery allowing for rapid penetration. In terms of market share, however, the segment of immunosuppressant lead the way with 21.3% share in the global Nanoemulsion market in 2016.
Request a Sample of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=15473
Emphasis on Product Development Drives North America Market
From a geographical perspective, North America at present dominates the global Nanoemulsion market. By expanding at a CAGR of 9.3%, the region is expected to pull in a revenue of US$5.96 bn in 2025. The dominant position of the region is a result of a well-established pharmaceutical and biotechnology industry, thrust on research activities for product development, and increasing prevalence of chronic disorders. Europe trails North America vis-à-vis market share. The revenue in the region is predicted to grow to US$5.217 by 2025.
While Europe and North America are dominant in the Nanoemulsion market in terms of size, Asia Pacific will likely run the show when it comes to growth pace by clocking the maximum CAGR of 9.4% during period between 2017 and 2025. The changing demographics and the increasing incomes of people in the region, particularly in the densely populated countries of China and India, are serving to drive growth in the region.
Latin America is another region that is projected to emerge as a profitable on account of governments’ initiatives to promote pharmaceutical and healthcare industries and the increasing healthcare expenditure. The Middle East and Africa Nanoemulsion market, on the other hand, is expected to grow because of the increasing number of products and initiatives by governments to promote research and development.
Prominent participants operating in the global market for Nanoemulsion are Mitsubishi Tanabe Pharma Corporation, Allergan plc, AbbVie Inc., AstraZeneca Inc., Fresenius Kabi AG, Kaken Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Novartis AG, Sanofi, and B. Braun Melsungen AG.